Here, we delineate the relative phenotype and function of FRβ+ and FRβ− TAMs and assess the therapeutic impact of targeting M2-like FRβ+ TAMs using a CAR-T cell strategy in murine models of ovarian cancer, colon cancer, and melanoma. Here, FOLR2 is linked to ovarian cancer.